Lilly and Novo Nordisk’s battle for weight loss drugs reaches pharmacies
Weight loss drug Zepbound gains ground in the US against Novo Nordisk’s Wegovy. Lilly has about 40% market share in the U.S., reaching 130,000 prescriptions in the week ending July 19, compared to Wegovy’s 200,000, according to IQVIA data.
BELIEBTE BEITRÄGE
UK sets new climate target for 2035
November 13, 2024
Children go back to school after Valencia floods
November 13, 2024
Researchers document huge decline in African elephants
November 13, 2024
Mission: Impossible 8 title revealed
November 13, 2024
LIVEÜBERTRAGUNG